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Abstract
Background: Single nucleotide polymorphisms (SNPs) rs7903146 and rs12255372 located within TCF7L2 gene have been
identified as the strongest common genetic risk factors for development of type 2 diabetes (T2D). We hypothesized that
these genetic variants might increase the risk of T2D through regulation of alternative splicing or expression level of TCF7L2
in human adipose tissue.
Methodology/Principal Findings: Expression of 13 assays detecting alternatively spliced forms of TCF7L2 was measured by
quantitative reverse-transcriptase PCR (qRT-PCR) in paired biopsies of omental and subcutaneous adipose tissue from 159
obese individuals (BMI 54.6+/212.2 kg/m
2). TCF7L2 expression in both types of adipose tissue was not associated with SNPs
rs7903146 and rs12255372, T2D status and blood levels of glucose or glycosylated hemoglobin (HbA1c). Expression of
assays ‘‘ex12-13’’, ‘‘ex12-14’’ and ‘‘ex13-13a’’ detecting C-terminal alternative exons of TCF7L2 was higher in subcutaneous
compared to omental adipose tissue by 1.46 fold (p=6.5610
215), 1.41 fold (p=1.4610
29) and 1.26 fold (p=4.7610
26)i n
the control group and by 1.86 fold (p=1.7610
24), 1.77 fold (p=7.3610
24) and 1.58 fold (p=6.1610
24) in the T2D group. A
pathway enrichment analysis on transcripts significantly co-expressed with TCF7L2 in a microarray set combined with
individual expression assays, suggested tissue-specific roles of TCF7L2 splicing forms in regulation of transcription, signal
transduction and cell adhesion.
Conclusions: Expression of TCF7L2 alternatively spliced forms may have different functional roles in omental and
subcutaneous adipose tissue but is not associated with SNPs rs7903146 and rs12255372 or T2D status.
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Introduction
Common intronic single nucleotide polymorphisms (SNPs)
within the transcription factor 7 - like 2 gene (TCF7L2) have
been identified as genetic factors that significantly increase risk of
type 2 diabetes (T2D) [1,2,3,4]. TCF7L2 belongs to a family of
TCF/LEF transcription factors that interact with b-catenin and
regulate the WNT pathway [5]. Activation of the WNT pathway
leads to increased cell proliferation due to effects of downstream
targets of TCF7L2 such as MYC [6,7] and CCND1 (Cyclin D1) [8].
A complex interplay of activation and repression of the WNT
pathway, orchestrated by different protein isoforms of TCF/LEF
transcription factors, is required for tissue-specific differentiation of
stem cells. For example, differentiation of skin stem cells into either
hair follicle or sebum-producing cells is regulated by expression of
alternatively spliced forms of the LEF1 transcription factor [9].
Similarly, an active WNT pathway is required for myogenesis,
while inactivation of the pathway by a dominant-negative form of
TCF7L2 promotes adipogenesis [10]. Increased adiposity, as
measured by body mass index (BMI), is a strong risk factor for
development of insulin resistance, T2D and cardiovascular disease
[11]. Several studies have reported that patients carrying risk
alleles of the associated SNPs rs7903146 and rs12255372 of
TCF7L2 have lower BMI compared to carriers of non-risk alleles
[12,13,14,15]. Potentially, risk alleles of TCF7L2 might increase
risk of T2D even in lean individuals, or affect diabetes and
adiposity through independent mechanisms.
Non-coding genetic variants can affect mRNA expression and
splicing [16,17]. Several studies attempted to correlate genotypes
of T2D-associated variants of TCF7L2 with mRNA expression of
TCF7L2 in adipose tissue [13,18] skeletal muscle [18], lympho-
blastoid cell lines [18] and pancreatic islets [19,20], but no
consistent associations have been reported. One study detected a
significant decrease in TCF7L2 expression in obese individuals
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only on six samples [13]. We previously catalogued and evaluated
expression of multiple splicing forms of TCF7L2 in several types of
human tissue [21]. We observed tentative association between
expression of several assays for C-terminal exons of TCF7L2 and
genotypes of SNPs rs7903146 and rs12255372 in pancreatic islets
but not in a small set of samples of subcutaneous adipose tissue
[21].
Here, we used 13 assays detecting all known splicing forms of
TCF7L2 to evaluate gene expression in paired biopsies of
subcutaneous and omental adipose tissue from 159 obese
individuals. We evaluated the association between expression of
these assays and genotypes of T2D-associated variants rs7903146
and rs12255372, T2D status, type of adipose tissue, BMI (37.6–
89.6 kg/m2) and blood levels of glucose and glycosylated
hemoglobin (HbA1c). We show that expression of alternatively
spliced forms of TCF7L2 may have different functional roles in
omental and subcutaneous adipose tissue but is not associated with
SNPs rs7903146 and rs12255372 or T2D status.
Results
Characteristics of the T2D and control groups
SNPs rs7903146 and rs12255372 are located in introns 3 and 4
of TCF7L2 gene within the associated linkage disequilibrium (LD)
block and 50 kb apart from each other [1,2,3] (Fig. 1). In our set of
159 Caucasian individuals, the frequencies of risk alleles of both
SNPs were higher in the T2D group (n=16) than in the control
group (n=143), 0.41 in T2D vs. 0.26 in controls for rs7903146
and 0.38 in T2D vs. 0.25 in controls for rs12255372 (Table 1).
Similarly to other European sets [1,2,3] and to the European set
(CEU) of the HapMap [22], these two SNPs were in high linkage
disequilibrium (LD) with each other (D9=0.88, r
2=0.73). Samples
in the T2D and control groups were matched by age, gender and
BMI by design but several T2D-related traits were significantly
different between these groups: levels of blood glucose, HbA1c and
homeostasis model of insulin resistance (Homa-IR) were increased,
while the level of HDL cholesterol was decreased in the T2D
group (Table 1).
Test for association between TCF7L2 expression and
genotypes of rs7903146 and rs12255372, T2D status and
blood levels of glucose and HbA1c
Levels of expression of 13 TCF7L2 assays in both types of
adipose tissue were adjusted for age, sex, BMI and blood levels of
glucose and HbA1c. Expression of these assays in each individual
tissue and the ratio of subcutaneous: omental expression was
similar in the control and T2D groups and in carriers of different
genotypes of SNPs rs7903146 and rs1225532 (Table 2 and 3).
Expression of assay ‘‘ex13-13b’’ (Fig. 1) previously studied in
human pancreatic islets [21] was tested but not detected in adipose
tissue (data not shown). Based on the number of samples and the
observed standard deviation in expression of each assay, we had
80% power and 95% confidence to detect a .1.2-fold difference
in expression between groups with risk and non-risk alleles for
each SNP and between the T2D and control groups.
Difference in TCF7L2 expression between omental and
subcutaneous adipose tissues
Expression of several assays was higher in subcutaneous
compared to omental adipose tissue both in the control and
T2D groups: 1.46 and 1.86-fold for assay ‘‘ex12-13’’, 1.41 and
1.77-fold for assay ‘‘ex12-14’’ and 1.26 and 1.58-fold for assay
‘‘ex13-13a’’ (Table 4). Only expression of alternative exon 3a
(assay ‘‘ex3a-4’’) was decreased in subcutaneous compared to
adipose tissue (0.81 fold) in the control group, but not in the T2D
group (0.91 fold) (Table 4). The results for assays ‘‘ex12-13’’, ‘‘13-
13a’’ and ‘‘12-14’’ will remain significant even after adjustment for
multiple tests. Different ways of normalization of TCF7L2
expression (by expression levels of endogenous controls B2M,
GAPDH or both genes together) did not significantly affect the
conclusions (data not shown). The assays ‘‘ex12-13’’, ‘‘13-13a’’
and ‘‘12-14’’ detect two distinct splicing forms that include
alternative exon 12 (Figure 2). The first form (GenBank FJ010174)
includes C-terminal exons 11-12-13-13a and encodes a protein
with a short reading frame terminated by an alternative stop
codon within exon 13a. The second form (GenBank FJ010170)
includes exons 11-12-14 and encodes a protein with a medium
Figure 1. Structure of TCF7L2 gene and location of expression assays. The scheme shows constitutive exons (black rectangles), alternative
exons (white rectangles); linkage disequilibrium (LD) block with associated SNPs rs7903146 and rs12255372; protein domains: ß-catenin-interacting
domain, DNA-binding HMG domain and C-terminal Binding Protein (CtBP)-binding domain; expression assays for detection of alternative splicing
forms of TCF7L2 are indicated by connected arrows: assays TSS1, TSS2 and TSS3 target transcripts produced from alternative transcription start sites
while other assays target alternatively spliced forms with different combinations of exons, * - expression of assay ‘‘ex13-13b’’ was tested but not
detected in adipose tissue.
doi:10.1371/journal.pone.0007231.g001
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beginning of exon 14 (Fig. 2).
Pathway enrichment analysis of TCF7L2 expression
To better understand the function of TCF7L2 in human adipose
tissue we searched for transcripts that positively or negatively
correlated with expression of TCF7L2. We combined global
expression data measured by microarrays [23] with data for
individual expression assays ‘‘ex7-8’’, ‘‘ex3a-4’’, ‘‘ex12-13’’ and
‘‘ex13-13a’’, generated in the same set of 159 samples of omental
and subcutaneous adipose tissue. On the microarrays, TCF7L2
was represented by 2 probes located within the 39 untranslated
Table 1. Characteristics of the T2D and control groups.
Trait T2D Mean (st.dev) T2D N Control Mean (st.dev) Control N p-value*
Age, years 46.53 (12.42) 16 43.78 (10.04) 143 0.30
Male: female ratio 52.9:47.1 16 47.6:52.4 143 0.68
BMI, Kg/m2 53.62 (15.77) 16 54.77 (11.73) 143 0.49
Cholesterol, mg/dl 167.0 (31.48) 15 189.98 (34.70) 130 0.0091
Triglycerides, mg/dl 205.73 (114.73) 14 168.69 (91.53) 129 0.18
Leptin, mg/dl 43.5 (27.58) 2 58.11 (31.19) 36 NA
LDL, mg/dl 93.6 (32.8) 14 110.77 (29.42) 127 0.016
HDL, mg/dl 37.19 (9.93) 15 46.63(11.65) 130 0.0004
WBC, 610
9 cell/l 9.16 (2.55) 15 8.41 (2.11) 139 0.22
Insulin, mg/dl 32.73 (25.53) 8 23.15 (14.16) 102 0.077
Glucose, mg/dl 197.82 (51.19) 16 98.04 (14.25) 143 2.04610
237
Homa-IR 316.21 (320.98) 8 102.11 (70.95) 102 5.58610
27
HbA1C 8.24 (1.30) 16 5.79 (0.59) 119 1.15610
223
Rs 7903146 32 268 0.097
C 0.594 0.738
T 0.401 0.262
Rs12255372 32 286 0.14
G 0.625 0.748
T 0.375 0.252
*Two-sided T-test or Chi-square test (for allele frequencies) not adjusted for covariates and multiple tests.
doi:10.1371/journal.pone.0007231.t001
Table 2. Expression of TCF7L2 in omental and subcutaneous adipose tissues: comparison between T2D and control groups, 119




b Effect in T2D
c SA p-value
b Effect in T2D
c
TSS1 0.054 0.130 + 0.327 +
TSS2 0.069 0.074 + 0.057 +
TSS3 0.050 0.064 + 0.052 +
Ex3a-4 0.106 0.054 2 0.128 +
Ex4-4a 0.200 0.141 + 0.067 +
Ex7-8 0.103 0.050 2 0.150 +
Ex11-13 0.074 0.095 + 0.290 +
Ex11-13a 0.151 0.078 + 0.430 +
Ex12-13 0.194 0.116 2 0.098 +
Ex13-13a 0.185 0.051 2 0.277 +
Ex12-14 0.054 0.055 2 0.051 +
Ex11-14 0.409 0.755 2 0.052 +
Ex13-14 0.134 0.051 2 0.197 +
SA-subcutaneous adipose, OA- omental adipose.
ain paired samples of subcutaneous and omental adipose tissue.
bp-values for univariate analysis, adjusted for age, sex, BMI and blood levels of glucose and HbA1c but not adjusted for multiple tests.
cincrease (+) or decrease (2) in expression in T2D group compared to controls.
doi:10.1371/journal.pone.0007231.t002
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probes and the assay ‘‘ex7-8’’ detect a mix of all splicing forms of
TCF7L2, while the assays ‘‘ex12-13’’, ‘‘ex13-13a’’ and ‘‘ex3a-4’’
detect distinct splicing forms that showed difference in expression
between the two types of adipose tissue. There was a significant
correlation between the microarray and TaqMan expression data
in omental adipose tissue: r2=0.51 for assay ‘‘ex7-8’’, r2=0.49 for
assay ‘‘ex13-13a’’, r2=0.42 for assay ‘‘ex12-13’’ and r2=0.31 for
‘‘ex3a-4’’ but in subcutaneous adipose tissue the correlation for the
same assays was not significant (r2,0.25). Using the joint
expression set (microarrays and TaqMan data), we identified sets
of transcripts that correlated with expression of these assays at a
cutoff of r2.+/20.25, corresponding to False Discovery Rate
(FDR) p,0.0015, and analyzed each set of transcripts for
enrichment of Gene Ontology categories (GO). In omental
adipose tissue TCF7L2 expression positively correlated with
activation of transcription through KRAB box Zn finger
transcription factors but negatively correlated with protein
biosynthesis, signal transduction, oxidative phosphorylation and
electron transport (Table 5). In subcutaneous adipose tissue the
strongest positive correlation was between expression of assay
‘‘ex13-13a’’ and the cadherin signaling pathway and cell adhesion,
Table 3. Effect of presence 0, 1 or 2 risk alleles of TCF7L2 SNPs on expression of TCF7L2 in paired omental and subcutaneous






















TSS1 0.368 0.168 0.341 0.288 0.306 0.186
TSS2 0.176 0.157 0.216 0.277 0.162 0.128
TSS3 0.166 0.170 0.185 0.143 0.533 0.358
Ex3a-4 0.075 0.081 0.079 0.072 0.114 0.064
Ex4-4a 0.203 0.069 0.204 0.064 0.064 0.109
Ex7-8 0.188 0.126 0.254 0.218 0.051 0.128
Ex11-13 0.269 0.070 0.285 0.221 0.068 0.147
Ex11-13a 0.122 0.331 0.485 0.217 0.274 0.583
Ex12-13 0.348 0.050 0.255 0.303 0.071 0.148
Ex13-13a 0.256 0.088 0.252 0.315 0.097 0.261
Ex12-14 0.137 0.055 0.111 0.174 0.133 0.056
Ex11-14 0.410 0.071 0.217 0.421 0.114 0.116
Ex13-14 0.187 0.085 0.135 0.178 0.102 0.066
SA-subcutaneous adipose, OA- omental adipose.
aratio subcutaneous:omental expression in paired samples.
bp-value for linear regression model with 0, 1 or 2 risk alleles of TCF7L2 SNPs adjusted for age, sex, BMI, T2D status and blood levels of glucose and HbA1c but not
adjusted for multiple tests.
doi:10.1371/journal.pone.0007231.t003















TSS1 1.0 1.06 0.20 1.0 1.13 0.29
TSS2 1.0 1.04 0.539 1.0 1.23 0.283
TSS3 1.0 1.00 0.066 1.0 1.20 0.353
Ex3a-4 1.0 0.81 2.6610
24 1.0 0.91 0.516
Ex4-4a 1.0 1.07 0.231 1.0 1.21 0.185
Ex7-8 1.0 1.08 0.047 1.0 1.24 0.056
Ex11-13 1.0 1.09 0.053 1.0 1.16 0.213
Ex11-13a 1.0 1.09 0.068 1.0 1.13 0.0013
Ex12-13 1.0 1.46 6.45610
215 1.0 1.86 1.7610
24
Ex13-13a 1.0 1.26 4.7610
26 1.0 1.58 6.1610
24
Ex12-14 1.0 1.41 1.4610
29 1.0 1.77 7.3610
24
Ex11-14 1.0 1.23 2.7610
24 1.0 1.49 0.0120
Ex13-14 1.0 1.13 0.0062 1.0 1.32 0.052
SA-subcutaneous adipose, OA- omental adipose.
*- Two-sided T-test, p-values are not adjusted for multiple tests; expression in omental adipose is taken as 1.0 for each assay.
doi:10.1371/journal.pone.0007231.t004
TCF7L2 in Human Adipose
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7231Figure 2. Alternative splicing forms of TCF7L2 with increased expression in subcutaneous compared to omental adipose. A.
Constitutive exons 11 and 14 are marked as black rectangles, alternative exons 12, 13, 13a, 13b are marked as white rectangles, black triangles above
exons indicate location of alternative stop codons that define protein reading frames: short (S), medium (M) or long (L); B. Alternative splicing form
with exons 11-12-13-13a (GenBank FJ010174) has an alternative stop codon within exon 13a and encodes a protein with short reading frame; C.
Alternative splicing form with exons 11-12-14 (GenBank FJ010170) has an alternative stop codon in the beginning of exon 14 and encodes a protein
with medium reading frame. Positions of expression assays ‘‘ex12-13’’, ‘‘ex13-13a’’ and ‘‘12-14’’ used in this study are indicated above corresponding
exons. Assays ‘‘ex12-13’’, ‘‘ex13-13a’’ and ‘‘12-14’’ detect all splicing forms of TCF7L2 that include alternative exon 12.
doi:10.1371/journal.pone.0007231.g002
Table 5. Panther Classification System analysis of TCF7L2 expression in adipose tissue.
Gene Ontology category Tissue, correlation






Ribosomal protein OA, N ex3a-4 473 31 5.15 + 3.23E-13
Protein biosynthesis OA, N ex3a-4 591 31 6.43 + 9.73E-11
Oxidative phosphorylation OA, N ex3a-4 85 13 .92 + 2.62E-09
Signal transduction OA, N ex3a-4 3412 10 37.12 2 6.33E-07
Electron transport OA, N ex3a-4 254 15 2.76 + 5.44E-06
Defense/immunity protein OA, N ex12-13 401 13 3.32 + 9.87E-04
Nucleic acid metabolism OA, P ex13-13a 3038 105 70.58 + 5.10E-04
Transcription factor OA, P ex13-13a 1796 71 41.73 + 2.41E-04
KRAB box transcription factor OA, P ex7-8 431 65 22.04 + 8.01E-12
Nucleic acid metabolism OA, P ex7-8 3038 233 155.37 + 3.51E-09
Zinc finger transcription factor OA, P ex7-8 727 80 37.18 + 4.92E-08
Cell surface receptor mediated signal transduction OA, P ex7-8 1596 36 81.62 2 5.52E-07
Receptor OA, P ex7-8 1476 33 75.49 2 3.51E-07
G-protein mediated signaling OA, P ex7-8 786 12 40.20 2 2.42E-05
Ribosomal protein SA, N ex3a-4 473 45 19.44 + 5.48E-05
Receptor SA, N ex12-13 444 42 18.20 + 2.81E-05
Cadherin SA, P ex13-13a 156 21 2.23 + 4.17E-12
Cadherin signaling pathway SA, P ex13-13a 214 21 3.05 + 1.57E-09
WNT signaling pathway SA, P ex13-13a 400 25 5.71 + 1.96E-07
Cell adhesion-mediated signaling SA, P ex13-13a 433 24 6.18 + 4.88E-06
OA – omental adipose; SA – subcutaneous adipose; P-positive correlation with TCF7L2, N-negative correlation with TCF7L2.
atranscripts with positive or negative correlation (r2.+/20.25, p,0.0015) with expression of TCF7L2 assays.
bnumber of transcripts in each GO category among 20,316 annotated transcripts on the array.
cnumber of transcripts with significant correlation with TCF7L2 expression in each GO category.
dexpected number of transcripts in each GO category based on the frequencies on the array.
edirection (enrichment or deficit) in each GO category.
fp-value for differences between observed and expected number of transcripts in each GO category Bonferroni-adjusted for number of GO categories.
doi:10.1371/journal.pone.0007231.t005
TCF7L2 in Human Adipose
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and receptor function (Table 5). Full list of transcripts with positive
and negative correlations with TCF7L2 assays ‘‘ex12-13’’ and
‘‘ex13-13a’’ are presented in Tables S2, S3, S4, S5.
Discussion
Our study provides a detailed analysis of expression of multiple
TCF7L2 splicing forms in paired biopsies of omental and
subcutaneous adipose tissue from a large set of obese individuals.
The first goal of this study was to evaluate the association between
the expression of TCF7L2 splicing forms and T2D-associated
SNPs rs7903146 and rs12255372, T2D status or blood levels of
glucose or HbA1c. Despite 80% of power to detect .1.2 fold
differences in expression between different groups, we did not
observe any significant association between these factors. Our
results are similar to a recently published data on 235 samples of
subcutaneous adipose tissue where expression of TCF7L2
(measured by one assay corresponding to our ‘‘ex7-8’’ assay) was
not affected by T2D status, sex, and genotypes of rs7903146 [24].
The second goal of this study was to compare the expression of
TCF7L2 splicing forms in two types of adipose tissue. We observed
that expression of assays ‘‘ex12-13’’, ‘‘ex12-14’’ and ‘‘ex13-13a’’
was higher in subcutaneous compared to omental tissue and this
difference could not be explained by genotypes of the T2D-
associated SNPs, sex, BMI and blood levels of glucose and HbA1c.
These findings were similar to the results of a study that did not
detect association between expression of assay ‘‘ex9-10’’ of
TCF7L2 and genotypes of rs7903146, rs12255372, age, sex and
BMI in paired biopsies of adipose tissue from 49 individuals [25].
However, the expression of this assay was 4.8-fold higher in
subcutaneous compared to omental tissue in controls and 6-fold
higher in the T2D group [25]. The effects observed in our study
were weaker, 1.46-fold in the control group and 1.86-fold in the
T2D group and the effect was not detectable for assay ‘‘ex7-8’’
that measures the same splicing forms as assay ‘‘ex9-10’’. This
could potentially be attributed to the difference in sample size (159
samples in our study and 49 samples in Kovacs et al.), use of
different custom-designed expression assays and reference genes
(one reference gene at Kovacs et al. and two reference genes in our
study). Additionally, individuals in our study were more obese
(BMI 54.6+/212.2) compared to less obese individuals in Kovacs
et al (BMI 29.7+/20.8 kg/m2) [25].
TCF7L2 is a ubiquitously expressed transcription factor that
mediates signals of the WNT pathway. The function of TCF7L2
and, particularly, in different types of adipose tissue is not clear. A
pathway enrichment analysis on transcripts significantly coex-
pressed with TCF7L2 showed that the main role of TCF7L2 in
omental adipose tissue is associated with activation of transcription
and inhibition of protein biosynthesis and signal transduction. In
contrast, in subcutaneous adipose tissue we did not observe any
evidence for correlation with activation of transcription, but with
increased cell adhesion through cadherin protein family (for assay
‘‘ex13-13a’’). Adipose consists of several types of cells such as
adipocytes, endothelial cells, macrophages that can differently
express TCF7L2. For example, assays ‘‘ex12-13’’ and ‘‘13-13a’’
specifically detect a unique splicing form that includes exons 12-
13-13a, expressed in multiple tissues and is the major TCF7L2
splicing form in peripheral blood monocytes ([21], GenBank
FJ010174, Figure 2). Adhesion of monocytes to endothelial lining
of capillaries, infiltration into adipose tissue and differentiation into
macrophages contributes to low-grade chronic inflammation in
adipose tissue and development of insulin resistance [20–22].
Therefore, increased expression of assays ‘‘ex12-13’’ and ‘‘ex13-
13a’’ in subcutaneous adipose tissue and co-expression with genes
involved in cell adhesion might indicate increased monocytes
influx into subcutaneous adipose tissue or other functional
differences between these two tissue types. All assays of TCF7L2
with significantly increased expression in subcutaneous compared
to omental adipose (‘‘ex12-13’’, ‘‘ex13-13a’’ and ‘‘ex12-14’’) detect
splicing forms that encode truncated TCF7L2 protein with short
or medium reading frames and include an alternative exon 12
(Figure 2). The truncated protein isoforms of TCF7L2 lack
binding sites for the CTBP protein are not post-translationally
regulated and may provide alternative regulation of the WNT
pathway [26].
In conclusion, we did not observe association between
expression of TCF7L2 splicing forms, T2D status and genotypes
of T2D-associated SNPs rs7903146 and rs12255372. Differential
expression of TCF7L2 splicing forms with alternative exon 12
encoding for truncated protein isoforms of TCF7L2 in omental
and subcutaneous adipose tissues deserves future studies.
Materials and Methods
Ethics Statement
The study on anonymized samples was approved by the
Internal Review Board (IRB) of Massachusetts General Hospital,
protocol #2001-P-001942/22 and exempted from IRB approval
at the NHGRI/NIH.
Tissue samples
Paired samples of omental and subcutaneous adipose tissue
were obtained from bariatric patients that underwent weight-
reduction surgery and signed informed consent forms [23].
Following traits were available for all or subsets of samples: age,
gender, BMI, white blood cells counts (WBC), fasting levels of
glucose, insulin, total cholesterol, HDL and LDL cholesterol,
triglycerides, homeostasis model of insulin resistance (Homa-IR)
and glycosylated hemoglobin (HbA1c). The T2D status was
assigned to individuals with fasting blood glucose higher than
140 mg/dl (7.8 mmol/L). Total RNA from flash-frozen adipose
samples was extracted using Trizol reagent (Invitrogen) and DNA
was isolated from liver samples of the same patients with DNeasy
kit (Qiagen).
Genotyping
Genotyping was performed with pre-developed TaqMan allelic
discrimination assays for rs7903146 and rs12255372 (Applied
Biosystems). The genotyping success was above 99% and only
samples genotyped for both markers were used.
Quantitative reverse-transcriptase PCR (qRT-PCR)
expression studies
cDNA was prepared from total RNA of selected samples of
omental and subcutaneous adipose tissue used for the microarray
expression studies [23]. For each sample, 100 ng of total RNA was
convereted to cDNA with SuperScript III reverse transcriptase
and random hexamers (Invitrogen). Expression assays for TCF7L2
were custom designed for each splicing form ([21] and Table S1).
Primers for SYBR Green assays were purchased from Integrated
DNA Technologies and TaqMan assays were manufactured on
demand by Applied Biosystems. qRT-PCR was performed in a
10 ul reaction volume in 384 well plates with Power SYBR Green
master mix (Applied Biosystems) or Expression Master Mix for
TaqMan assays (Applied Biosystems) on the Sequence Detection
System 7900 (Applied Biosystems). Each expression assay was run
in technical duplicates and the average values for each sample
TCF7L2 in Human Adipose
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genes beta 2 microglobulin (B2M, assay Hs00187842_m1, Applied
Biosystems) and Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, assay 4333764F, Applied Biosystems) run in separate
reactions from the same cDNA preparations.
Statistical analyses
qRT-PCR expression was measured in Ct values (PCR cycle at
which expression was detected). For each sample and assay, the
average of technical replicates was first normalized to a geometric
mean values of reference genes, B2M and GAPDH according to
the formula: Ct(geometric)=(Ct(B2M)+Ct(GAPDH))/2. Relative
expression of each assay was calculated as: dCt=Ct(geome-
tric)2Ct(assay). For each assay, the dCt values were first tested for
normality of distribution. The association between expression of
TCF7L2 assays and the counts of risk alleles (0, 1, 2) of the T2D-
associated SNPs rs7903145 and rs12255372 was tested with
univariate linear regression model with adjustment for covariates
(age, sex, and log-transformed values of BMI and blood levels of
glucose and HbA1c). The analyses were performed with SPSS
16.0 (SPSS Inc.). Microarray expression was analyzed with R
statistical programming package. Power analysis was performed
with StatMate 2.0 (GraphPad) and was based on standard
deviations in expression of each of assays, number of samples
with 0 or 1 and 2 risk alleles at each SNP and 80% power to detect
the difference with 5% of type I error.
Joint analysis of the microarray and TaqMan data,
pathway enrichment analysis
The microarray data for 159 paired samples of omental and
subcutaneous adipose tissue was a part of a previously described
study [23]. The microarray data was available to all authors of the
article and is available upon request. Each of the RNA samples
was profiled with custom-designed microarrays that included
39,280 oligonucleotide probes representing 34,266 known and
predicted genes (Agilent Technologies, Palo Alto, CA). We used
assays ‘‘ex3a-4’’, ‘‘ex7-8’’, ex’’12-13’’ and ‘‘ex13-13a’’ of TCF7L2
for joint analysis of expression. Expression of B2M and GAPDH
was used as an endogenous control for TaqMan TCF7L2
expression. However, when we combined the TaqMan and
microarray data, we observed that the sets of transcripts that
correlated with TCF7L2 expression significantly overlapped with
the set of transcripts that correlated with GAPDH and B2M
expression. To remove this biologically relevant variation
component from the GAPDH and B2M expression, we identified
a set of transcripts that correlated with the geometric mean of B2M
and GAPDH expression at a 5% FDR (false-discovery rate). We
then performed Principal Component Analysis on this set of
transcripts to identify those factors (eigenvectors) that explained
greater than 90% of the variation in the GAPDH/B2M geometric
mean and adjusted the GAPDH/B2M expression by each of these
eigenvectors. The adjusted B2M/GAPDH expression was then
used to normalize TCF7L2 expression using standard linear
regression methods. For co-expression analysis, the normalized
expression values for all transcripts were adjusted for age and sex
and the residuals were computed using the rlm function from the
R statistical package (M-estimation with Tukey’s bisquare
weights). The Spearman correlation coefficients for expression of
TCF7L2 and all other transcripts were calculated. The FDR for
these correlations was calculated by performing 1000 permuta-
tions of sample IDs while preserving the correlation structure
among the gene expression values. The threshold for Spearman
coefficient was set up at r=+/20.25, corresponding to FDR,1%
(p-value,0.0005). The pathway enrichment analysis on sets of
transcripts with significant correlations was performed using the
Panther Classification System [27]. For each GO category, we
compared expected and observed frequencies between a set of
20,316 annotated transcripts presented on the array and the sets of
transcripts significantly correlated with TCF7L2 expression. The p-
value for significance of enrichment in each group was adjusted for
the number of GO categories using Bonferroni method imple-
mented in the Panther analysis [27].
Supporting Information
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